 | Up a level |
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
Procter, Marion; Suter, Thomas M; de Azambuja, Evandro; Dafni, Urania; van Dooren, Veerle; Muehlbauer, Susanne; Climent, Miguel Angel; Rechberger, Ernst; Liu, Walter Tsang-Wu; Toi, Mazakasu; Coombes, R Charles; Dodwell, David; Pagani, Olivia; Madrid, Jorge; Hall, Marcia; Chen, Shin-Cheh; Focan, Christian; Muschol, Michael; van Veldhuisen, Dirk J and Piccart-Gebhart, Martine J (2010). Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. Journal of clinical oncology, 28(21), pp. 3422-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2009.26.0463
Suter, Thomas M; Procter, Marion; van Veldhuisen, Dirk J; Muscholl, Michael; Bergh, Jonas; Carlomagno, Chiara; Perren, Timothy; Passalacqua, Rodolfo; Bighin, Claudia; Klijn, Jan G M; Ageev, Fail T; Hitre, Erika; Groetz, Juergen; Iwata, Hiroji; Knap, Malgorzata; Gnant, Michael; Muehlbauer, Susanne; Spence, Alison; Gelber, Richard D and Piccart-Gebhart, Martine J (2007). Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. Journal of clinical oncology, 25(25), pp. 3859-65. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.09.1611
